OSUCCC – James at International Conferences

OSUCCC – James at the American Association for Cancer Research® (AACR) Annual Meeting 2025

Connect with our researchers and physician-scientists April 25-30 at the American Association for Cancer Research® (AACR) Annual Meeting 2025.

Join us for Ohio State’s Scarlet and Gray Reception.

Register to attend

OSUCCC – James at the American Association for Cancer Research® (AACR) Annual Meeting 2025

Join us for Ohio State’s Scarlet and Gray Reception during the AACR Annual Meeting.

Saturday, April 26
6:30-8:30 p.m.

Hilton Chicago, Buckingham Room
720 South Michigan Avenue
Chicago, Illinois 60605

Register to attend


Fellow of the AACR Academy

Electra Paskett, PhD, MSPH

Electra Paskett, PhD, MSPH, FACE
Deputy Director for Population sciences and Community Outreach
Director of the Center for Community Outreach and Engagement
OSUCCC – James

The mission of the Fellows of the AACR Academy is to recognize and honor extraordinary scientists whose groundbreaking contributions have driven significant innovation and progress in the fight against cancer. Fellows of the AACR Academy constitute a global brain trust of leading experts in cancer science and medicine, working to advance the AACR’s mission to prevent and cure all cancers through research, education, collaboration, communication, advocacy, and funding for cancer research.


Presentations and sessions by OSUCCC – James experts at AACR

Learn more about specific presentations and sessions by OSUCCC – James experts at the American Association for Cancer Research® (AACR) Annual Meeting 2025.

Poster Sessions

Monday, April 28, 9 a.m. – 12 p.m.

Author: Christian Showalter, PhD
Session Title: Radiation Sciences 1
Poster#: 4
Title: Deciphering PSMA7 modulation by RT and TMZ for enhanced GBM treatments

Author: Ganesh Yadaigiri
Session Title: Novel Antitumor Agents 1
Poster#: 24
Title: A novel small molecule inhibitor, HO-4200, modulates macrophage polarization and suppresses MDSCs to enhance antitumor immune responses in ovarian cancer

Monday, April 28, 2 – 5 p.m.

Author: Merve Hasanov, MD
Session Title: Prognostic Biomarkers 2
Poster#: 14
Title: The 31-gene expression profile identifies patients at risk of developing early distant metastases and can guide risk-appropriate surveillance strategies

Author: Marisa Bittoni, PhD, MS
Session Title: The Role of Physical Activity, Diet, Microbiome, Obesity, and Energy Balance in the Cancer Continuum
Poster#: 5
Title: The BE FIT study: feasibility of an exercise intervention on the microbiome and immune function in a high-risk cohort for lung cancer

Author: Faiza Kalam, PhD
Session Title: The Role of Physical Activity, Diet, Microbiome, Obesity, and Energy Balance in the Cancer Continuum
Poster#: 4
Title: Extracellular vesicle dynamics in alternate-day fasting combined with low-carbohydrate weight loss intervention

Tuesday, April 29, 9 a.m. – 12 p.m.

Author: Min-Ae Song
Session Title: Late-Breaking Research: Molecular/Cellular Biology and Genetics 2
Poster#: 4
Title: Epigenetic age in normal breast tissues and its association with breast cancer risk factors

Author: Asrar Alahmadi
Session Title: Phase I Clinical Trials in Progress 2
Poster#: 16
Title: An open-label phase 1 study to investigate JBZ001 in adults with advanced solid tumors and non-Hodjkin lymphoma (JBZ001, Trial in Progress)

Author: Gautam Sarathy
Session Title: Regulation of Gene Expression in Drug Resistance
Poster#: 6
Title: Enhancing chemotherapeutic activity against triple-negative breast cancer cells using induced electric fields

Author: Federica Calore, PhD
Session Title: Late-Breaking Research: Clinical Research 2 / Endocrinology
Poster#: 13
Title: Evaluating TRAP1 as a novel, potential therapeutic target in dedifferentiated liposarcoma

Tuesday, April 29, 2 – 5 p.m.

Author: Cuthbert Mahenge, MD, MPH
Session Title: Health Disparities and Systemic Inequities: Lifestyle, Metabolism, and Disparities in Cancer Risk and Outcomes
Poster#: 13
Title: Impact of body composition on tumor proteomics and survival outcomes in clear cell renal cell carcinoma

Author: Holli Loomans-Kropp, PhD
Session Title: Development of Chemopreventive Agents and Preclinical Models
Poster#: 9
Title: Metformin induces cell cycle arrest and inhibits proliferation in KRAS-mutated colorectal cancer

Wednesday, April 30, 9 a.m – 12 p.m.

Author: Rand Lucine Akasheh, PhD
Session Title: Socioeconomic, Lifestyle, and Biological Drivers of Cancer Risk and Survival: Clinical Outcomes and Treatment Guidelines
Poster#: 2
Title: Body size and composition in relation to PI3K/AKT/mTOR signaling: insights into cancer risk and outcomes - a systematic review

Author: Holli Loomans-Kropp, PhD
Session Title: Innovations in Prevention and Cancer Care: Addressing Disparities, Inflammation, Survivorship, and Modifiable Risk Factors
Poster#: 17
Title: Systemic chronic inflammation is associated with quality of life in the Cancer Disparities Research Network

 

Featured news story

Dr. Parwani reviewing a digital slide

Ohio State drug discovery enters clinical testing, secures commercialization partner

A new therapeutic agent developed at The Ohio State University will be used for cancer treatment in a clinical trial. The trial, led by the OSUCCC – James, will test a best-in-class DHODH inhibitor discovered and developed at Ohio State.

Read the article


Featured Experts

Electra Paskett, PhD, MSPH

Electra Paskett, PhD, MSPH, FACE
Deputy Director, Population Sciences and Community Outreach
Director, Center for Community Outreach and Engagement



Chyke A Doubeni, MBBS, MPH

Chyke A Doubeni, MBBS, MPH
Associate Director, The Ohio State University Comprehensive Cancer Center



Clinical Trials

The OSUCCC – James is one of only a few comprehensive cancer centers funded by the National Cancer Institute (NCI) to conduct phase I and phase II clinical trials on novel anticancer drugs.

Search all clinical trials


Follow the OSUCCC – James on social media

#AACR2025, Facebook @OSUCCCJames, Twitter @OSUCCC_James, and LinkedIn.

Related Videos

The James at AACR 2025

Featured news and articles

Lab Scientist

Look for the OSUCCC – James at these conferences

OSUCCC – James experts will be at several upcoming international meetings and conferences; several are listed below. We hope to see you there.

  • OSUCCC – James at SITC 2024
  • OSUCCC – James at ASH 2024
  • OSUCCC – James at Arab Health 2025
  • OSUCCC – James at SGO 2025
  • OSUCCC – James at the American Association for Cancer Research® (AACR) Annual Meeting 2025
  • OSUCCC – James at ASPO 2025
  • OSUCCC – James at ASCO 2025
  • OSUCCC – James at ASTRO 2025


Partner with the OSUCCC – James

Find a Clinical Trial

Find a Clinical Trial

Discover hundreds of clinical trials that offer patients access to the latest treatments.

Find a Clinical Trial
Media Inquiries

Media Inquiries

Mary Ellen Fiorino, Media Relations: 614-293-3737 weekdays and 614-293-8000 nights/weekends.

Contact media relations
For Cancer Researchers

For Cancer Researchers

We have one of the most comprehensive cancer research programs in the United States.

Explore research programs